Login to Your Account



Financings NEWS

Fluorine-focused Scifluor Life Sciences Inc. pulled down $30 million that should "allow us to get into what we suspect will be four phase I trials" with a pair of compounds – including eye drops for AMD – and provides "at least a two-year runway," noted CEO Omar Amirana.

T CELLS AND BEYOND
Transitioning from discovery stage to human proof of concept is the next goal for cancer immunotherapy firm Jounce Therapeutics Inc., which added $56 million in series B funding to advance its pipeline and move into the clinic with a lead program directed against inducible T-cell co-stimulator, or ICOS.
Dimension Therapeutics Inc.'s $65 million series B financing lets the firm push its adeno-associated virus (AAV) platform and the growing pipeline of gene therapy programs.
More Financings Headlines

Cast Your Vote

Has biotech’s bubble burst?: